Every simplified-issue carrier on our panel asks whether you have ever had — or been advised to have — an organ or bone marrow transplant, and a yes ends the application. There is no time credit: a kidney transplant ten years ago answers exactly the same as one last spring. The “advised to have” wording (Mutual of Omaha, American Amicable, Foresters, Royal Neighbors) captures anyone on a waiting list, and Transamerica adds a separate rule for anyone advised or planning surgery under general anesthesia. Anti-rejection medications — tacrolimus, mycophenolate, cyclosporine, sirolimus, azathioprine — appear on published drug lists as no-coverage, so the prescription check catches what a question might miss.
The exceptions are narrow and honest. Transamerica’s 2019 guide treats a self-donated (autologous) stem-cell or tissue transplant as a Preferred condition — worth confirming against the current guide for anyone whose “transplant” was their own cells. And Banner’s fully underwritten term will refer kidney or liver recipients aged 40 and over, and bone-marrow or stem-cell recipients, to an underwriter for individual consideration rather than an automatic decline.
Beneath everything sits the floor that never asks: guaranteed-issue whole life. Mutual of Omaha’s runs to age 85, Corebridge’s and Americo’s to 80. A two-year graded period (three at Americo) applies to natural-cause death; accidents are covered in full from day one; premiums never rise; the full benefit locks in for life.